133 related articles for article (PubMed ID: 32505734)
1. Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer.
Sharpnack MF; Cho JH; Johnson TS; Otterson GA; Shields PG; Huang K; Carbone DP; He K
Lung Cancer; 2020 Aug; 146():36-41. PubMed ID: 32505734
[TBL] [Abstract][Full Text] [Related]
2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
3. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
4. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
5. Advanced Non-Small Cell Lung Cancer Patients With Low Tumor Mutation Burden Might Derive Benefit From Immunotherapy.
Nie W; Xu MD; Gan L; Zhang Y; Qian J; Gu K; Zhang XY; Wang HM; Yan B; Gu P; Zhang B; Wang SY; Hu F; Li CH; Zhong H; Han BH
J Immunother; 2020; 43(6):189-195. PubMed ID: 32209830
[TBL] [Abstract][Full Text] [Related]
6. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
Chen H; Chong W; Teng C; Yao Y; Wang X; Li X
Cancer Sci; 2019 Aug; 110(8):2348-2356. PubMed ID: 31222843
[TBL] [Abstract][Full Text] [Related]
7. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
[TBL] [Abstract][Full Text] [Related]
8. Integrating POLE/POLD1 mutated for immunotherapy treatment planning of advanced stage non-small cell lung cancer.
Zheng S; Cao Y; Randall J; Yu H; Thomas TO
Thorac Cancer; 2023 Aug; 14(23):2269-2274. PubMed ID: 37345618
[TBL] [Abstract][Full Text] [Related]
9. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
Li M; Gao X; Wang X
Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
[TBL] [Abstract][Full Text] [Related]
10. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
12. Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Non-Small-Cell Lung Cancer.
Zhang N; Wu J; Yu J; Zhu H; Yang M; Li R
Clin Lung Cancer; 2020 May; 21(3):e151-e163. PubMed ID: 31734072
[TBL] [Abstract][Full Text] [Related]
13. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
[TBL] [Abstract][Full Text] [Related]
15. Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.
Li Y; Jiang W; Li T; Li M; Li X; Zhang Z; Zhang S; Liu Y; Zhao W; Gu Y; Qi L; Ao L; Guo Z
J Transl Med; 2020 Jan; 18(1):25. PubMed ID: 31937321
[TBL] [Abstract][Full Text] [Related]
16. Tumor Mutational Burden Is Site Specific in Non-Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases.
Stein MK; Pandey M; Xiu J; Tae H; Swensen J; Mittal S; Brenner AJ; Korn WM; Heimberger AB; Martin MG
JCO Precis Oncol; 2019 Dec; 3():1-13. PubMed ID: 35100709
[TBL] [Abstract][Full Text] [Related]
17. Association of
Jia M; Yao L; Yang Q; Chi T
Front Oncol; 2020; 10():168. PubMed ID: 32154170
[TBL] [Abstract][Full Text] [Related]
18. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
[TBL] [Abstract][Full Text] [Related]
19. A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.
Pan D; Hu AY; Antonia SJ; Li CY
J Thorac Oncol; 2021 Mar; 16(3):419-427. PubMed ID: 33307194
[TBL] [Abstract][Full Text] [Related]
20. Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC of Never Smokers.
Ruel LJ; Li Z; Gaudreault N; Henry C; Saavedra Armero V; Boudreau DK; Zhang T; Landi MT; Labbé C; Couture C; Desmeules P; Joubert P; Bossé Y
Cancer Epidemiol Biomarkers Prev; 2022 Dec; 31(12):2219-2227. PubMed ID: 36126278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
